phosphonoacetic acid has been researched along with HIV Coinfection in 10 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 7.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 3.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| " The serious toxicity associated with zidovudine has led researchers to develop safer dosage regimens." | 2.38 | Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. ( Cersosimo, RJ; Matthews, SJ; Spivack, ML, 1991) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (90.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, E | 1 |
| Kim, S | 1 |
| Hong, JH | 1 |
| Butler, KM | 1 |
| De Smet, MD | 1 |
| Husson, RN | 1 |
| Mueller, B | 1 |
| Manjunath, K | 1 |
| Montrella, K | 1 |
| Lovato, G | 1 |
| Jarosinski, P | 1 |
| Nussenblatt, RB | 1 |
| Pizzo, PA | 1 |
| Jacobson, MA | 2 |
| Molina, JM | 1 |
| David, F | 1 |
| Scieux, C | 1 |
| Schnell, L | 1 |
| Gerrier, F | 1 |
| Kateb, M | 1 |
| Morinet, F | 1 |
| Modai, J | 1 |
| Smith, KJ | 1 |
| Kahlter, DC | 1 |
| Davis, C | 1 |
| James, WD | 1 |
| Skelton, HG | 1 |
| Angritt, P | 1 |
| Matthews, SJ | 1 |
| Cersosimo, RJ | 1 |
| Spivack, ML | 1 |
| Jacobsen, MA | 1 |
| van der Horst, C | 1 |
| Causey, DM | 1 |
| Dehlinger, M | 1 |
| Hafner, R | 1 |
| Mills, J | 1 |
| O'Donnell, JJ | 1 |
| Henderly, DE | 1 |
| Jampol, LM | 1 |
| Cotton, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy[NCT00001002] | Phase 1 | 12 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for phosphonoacetic acid and HIV Coinfection
| Article | Year |
|---|---|
Foscarnet therapy for AIDS-related opportunistic herpesvirus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Comb | 1992 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; H | 1991 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
6 other studies available for phosphonoacetic acid and HIV Coinfection
| Article | Year |
|---|---|
Synthesis of novel 2',3'-difluorinated 5'-deoxythreosyl phosphonic acid nucleosides as antiviral agents.
Topics: Acetates; Adenine; Anti-HIV Agents; Benzophenones; Chromatography, Thin Layer; Drug Design; Glyceral | 2015 |
Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.
Topics: Antiviral Agents; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Female; F | 1992 |
[Type 1 herpesvirus cutaneo-mucous infection resistant to aciclovir in a HIV infected patient. Clinical and virological study].
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Infec | 1992 |
Acyclovir-resistant varicella zoster responsive to foscarnet.
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Zoster; Herpesviru | 1991 |
In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Foscarnet; Gen | 1991 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Inf | 1990 |